165 related articles for article (PubMed ID: 18045851)
21. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
[TBL] [Abstract][Full Text] [Related]
22. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
Cheng G; Liu D; Margetts P; Liu L; Zhao Z; Liu Z; Tang L; Fang Y; Li H; Guo Y; Chen F; Liu F
Nephrology (Carlton); 2015 Feb; 20(2):77-84. PubMed ID: 25358874
[TBL] [Abstract][Full Text] [Related]
23. Control of hypertension with captopril affords better renal protection as compared with irbesartan in salt-loaded uremic rats.
Weissgarten J; Berman S; Efrati S; Rapoport M; Modai D; Cohn M; Aladjem M; Galperin E; Averbukh Z
Nephron Physiol; 2005; 101(1):p14-20. PubMed ID: 15925907
[TBL] [Abstract][Full Text] [Related]
24. The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure.
Ziai F; Ots M; Provoost AP; Troy JL; Rennke HG; Brenner BM; Mackenzie HS
Kidney Int Suppl; 1996 Dec; 57():S132-6. PubMed ID: 8941934
[TBL] [Abstract][Full Text] [Related]
25. Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events.
; ; Connolly S; Yusuf S; Budaj A; Camm J; Chrolavicius S; Commerford PJ; Flather M; Fox KA; Hart R; Hohnloser S; Joyner C; Pfeffer M; Anand I; Arthur H; Avezum A; Bethala-Sithya M; Blumenthal M; Ceremuzynski L; De Caterina R; Diaz R; Flaker G; Frangin G; Franzosi MG; Gaudin C; Golitsyn S; Goldhaber S; Granger C; Halon D; Hermosillo A; Hunt D; Jansky P; Karatzas N; Keltai M; Lanas F; Lau CP; Le Heuzey JY; Lewis BS; Morais J; Morillo C; Oto A; Paolasso E; Peters RJ; Pfisterer M; Piegas L; Pipillis T; Proste C; Sitkei E; Swedberg K; Synhorst D; Talajic M; Trégou V; Valentin V; van Mieghem W; Weintraub W; Varigos J
Am Heart J; 2006 Jun; 151(6):1187-93. PubMed ID: 16781218
[TBL] [Abstract][Full Text] [Related]
26. AT1-receptor antagonism in hypertension: what has been learned with irbesartan?
Waeber B; Burnier M
Expert Rev Cardiovasc Ther; 2003 May; 1(1):23-33. PubMed ID: 15030294
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases.
Franscini LM; Von Vigier RO; Pfister R; Casaulta-Aebischer C; Fossali E; Bianchetti MG
Am J Hypertens; 2002 Dec; 15(12):1057-63. PubMed ID: 12460701
[TBL] [Abstract][Full Text] [Related]
28. Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats.
Carraway JW; Park S; McCune SA; Holycross BJ; Radin MJ
J Cardiovasc Pharmacol; 1999 Mar; 33(3):451-60. PubMed ID: 10069682
[TBL] [Abstract][Full Text] [Related]
29. The value of irbesartan in the management of hypertension.
Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
[TBL] [Abstract][Full Text] [Related]
30. [Slowing the progression of chronic renal insufficiency with captopril in rats with spontaneous arterial hypertension and adriamycin nephropathy].
Jovanović DB; Jovović Dj; Varagić J; Dimitrijević J; Dragojlović Z; Djukanović L
Srp Arh Celok Lek; 2002; 130(3-4):73-80. PubMed ID: 12154518
[TBL] [Abstract][Full Text] [Related]
31. Effect of irbesartan on the antioxidant defence system and nitric oxide release in diabetic rat kidney.
Anjaneyulu M; Chopra K
Am J Nephrol; 2004; 24(5):488-96. PubMed ID: 15353911
[TBL] [Abstract][Full Text] [Related]
32. Increased osteopontin expression following renal ablation is attenuated by angiotensin type 1 receptor antagonism.
Cao Z; Cox A; Bonnet F
Exp Nephrol; 2002; 10(1):19-25. PubMed ID: 11803201
[TBL] [Abstract][Full Text] [Related]
33. Effects of irbesartan on inflammatory cytokine concentrations in patients with chronic glomerulonephritis.
Tsuruoka S; Kai H; Usui J; Morito N; Saito C; Yoh K; Yamagata K
Intern Med; 2013; 52(3):303-8. PubMed ID: 23370736
[TBL] [Abstract][Full Text] [Related]
34. Optimizing antiplatelet therapy in high-risk patients with atrial fibrillation: insights from Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE A).
Seet RC; Chen CP
Stroke; 2009 Dec; 40(12):3883-5. PubMed ID: 19875732
[No Abstract] [Full Text] [Related]
35. Influence of irbesartan and enalapril on changes of renal function associated with the established phase of l-NAME hypertension.
Jover B; Herizi A; Casellas D; Mimran A
J Hypertens; 2001 Nov; 19(11):2039-46. PubMed ID: 11677370
[TBL] [Abstract][Full Text] [Related]
36. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
Croom KF; Curran MP; Goa KL; Perry CM
Drugs; 2004; 64(9):999-1028. PubMed ID: 15101793
[TBL] [Abstract][Full Text] [Related]
37. Treatment with irbesatan may improve slit diaphragm alterations in rats with adriamycin-induced nephropathy.
Wang N; Wei RB; Li P; Li QP; Yang X; Yang Y; Huang MJ; Wang R; Yin Z; Lv Y; Chen XM
J Renin Angiotensin Aldosterone Syst; 2016; 17(2):1470320316646884. PubMed ID: 27169889
[TBL] [Abstract][Full Text] [Related]
38. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria.
Andersen S; Bröchner-Mortensen J; Parving HH;
Diabetes Care; 2003 Dec; 26(12):3296-302. PubMed ID: 14633817
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
Palmer AJ; Annemans L; Roze S; Lamotte M; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH
Diabetes Care; 2004 Aug; 27(8):1897-903. PubMed ID: 15277414
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
Berl T; Hunsicker LG; Lewis JB; Pfeffer MA; Porush JG; Rouleau JL; Drury PL; Esmatjes E; Hricik D; Parikh CR; Raz I; Vanhille P; Wiegmann TB; Wolfe BM; Locatelli F; Goldhaber SZ; Lewis EJ;
Ann Intern Med; 2003 Apr; 138(7):542-9. PubMed ID: 12667024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
